Overview
This pooled analysis investigates death outcomes in patients with pharmacologically treated and blood pressure-controlled hypertension. Despite documented BP control, some patients still suffer fatal cardiovascular, cerebrovascular, renal, or unexplained syndromes. This study aims to synthesize available evidence across study types to identify treatment pitfalls, contributing syndromes, and non-BP factors associated with these fatal outcomes.
Description
Although hypertension is commonly treated and controlled to target levels, fatalities still occur in some patient subgroups. This pooled review seeks to identify and analyze these populations' contributing factors, comorbidities, treatment contexts, and physiological mechanisms associated with mortality. Data will be collected from peer-reviewed studies and registries. Statistical analysis will include descriptive synthesis, subgroup tabulations, and exploratory regression.
Open-label analysis aims to investigate death outcomes among patients with treated and well-controlled hypertension by synthesizing results from published clinical trials, observational studies, and systematic reviews.
The study will statistically evaluate endpoint include fatal cardiovascular, cerebrovascular, renal, or vascular events in patients in any arm with documented blood pressure control, with clearly seen evidence.
Eligibility
Inclusion criteria
- Human studies (RCTs, cohort, case-control, registry studies, etc.) declare participants with treated and controlled hypertension manage (regardless of drug class, duration, or comorbidity) reported mortality outcomes: all-vascular death, cardiovascular death, sudden death, etc.
- Studies in any setting (outpatient, inpatient, long-term follow-up)
- Articles in English
- Full-text available
Exclusion criteria
- Animal specimen or parameter studies
- Uncontrolled studies (e.g., case series without control, phase I safety trials)
- No mortality endpoint reported
- Purely mechanistic studies or trials that do not address BP or survival directly
- Pediatric studies unless separated subgroup for treated hypertension is available
- Glaucoma or portal hypertension or Pulmonary Hypertension without essential/systemic hypertension outcomes
- Infection without direct declare that septic shock or immunological failure associated by vascular cause from systemic hypertension
- Secondary/post-hoc analyses that do not report original mortality data